| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.9 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.0062 | 0.9 |
| mRNA | BIX-01294 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.0055 | 0.9 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.01 | 0.9 |